Plain-English translation of NCT05894369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at blood samples from patients with esophageal squamous cell carcinoma (a type of esophageal cancer) who are receiving chemotherapy combined with immunotherapy before surgery. Researchers want to understand how inflammation in your body and changes in your tumor's microenvironment (the area around cancer cells) affect how well this medication works for you.
Doctors know that chemotherapy combined with immunotherapy helps some patients with esophageal cancer, but it doesn't work equally well for everyone. This study aims to find blood markers that can predict which patients will benefit most from this treatment and understand the biological reasons why.
You likely qualify if…
You likely don't qualify if…
You would continue your scheduled chemotherapy and immunotherapy treatment as planned. Before you start treatment, after 2 cycles, and after 4 cycles, researchers will collect blood samples and basic health information. They will also review your CT scans or gastroscopy results, which are part of your routine care. The study runs from May 2023 through December 2024, and the time commitment involves only the extra blood draws at these three time points—no additional visits beyond your regular appointments.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Sponsor
Renmin Hospital of Wuhan University
Enrollment target
~10 participants
Started
May 2023
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yong Shun Chen
Renmin Hospital of Wuhan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.